BioGenCell
About:
BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease.
Website: http://www.biogencell.net/
Top Investors: Marius Nacht
Description:
BioGenCell designs cellular therapies that treat blood flow problems in the limbs, a side effect of diabetes and heart disease. Its technology creates autologous cells, derived from the patients themselves, to repair themselves. Its lead product, BC1, uses the company's technology to treat blood vessel insufficiency that can cause multiple organ failure in diabetic patients. Derived from the patient's own adult stem cells, its easy-to-use and cost-effective therapies can regenerate damaged tissues, with the eventual goal of treating a wide range of degenerative diseases including diabetes, heart failure, stroke, blindness, cancer, and immunological diseases. Its patented technology platform provides a comprehensive solution for most aspects of cellular therapy and supports rapid manufacturing and long-term storage (bio-banking) of therapeutic cellular products for use in patient treatment.
$16M
$1M to $10M
Netanya, HaMerkaz, Israel
2008-01-01
debbie.mahfud(AT)biogencell.net
Eyal Peleg
1-10
2022-05-09
Private
© 2025 bioDAO.ai